Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
53
Not yet recruiting, industry sponsors, Immunology and inflammation, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting150
- Completed727
53 trials
Showing 1 to 25, recently updated first.
- An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)Not yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07923747 · 90 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 20, 2029
Drug: DKB903 · For: Rheumatoid Arthritis and Systemic Lupus Erythematosus
NCT07934472 · 25 participants (planned) · Start Nov 15, 2026 · Primary completion Dec 31, 2028
Drug: Dapirolizumab pegol (DZP) · For: Systemic Lupus Erythematosus
Innatus Therapeutics (Shanghai) Co., Ltd.Industry
NCT07941388 · 92 participants (planned) · Start Nov 9, 2026 · Primary completion Jun 17, 2027
Drug: INT-1868 Tablets; INT-1868 Tablets and 2 more · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic DermatitisNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07920809 · 60 participants (planned) · Start Nov 2026 · Primary completion Sep 2027
Drug: HSK60002 tablets; HSK60002 Placebo · For: Dermatitis Atopic
- MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)Not yet recruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT07938606 · 24 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: MG-K10 humanized monoclonal antibody injection · For: Atopic Dermatitis
Sites: Shanghai, China
- Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe EczemaNot yet recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT07932795 · 56 participants (planned) · Start Dec 20, 2026 · Primary completion Aug 14, 2028
Drug: M5542 · For: Eczema
Sites: Darmstadt, Germany
- An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesNot yet recruiting
SanofiSanofi (SNY)
NCT07923383 · 25 participants (planned) · Start Nov 3, 2026 · Primary completion Aug 8, 2028
Drug: Duvakitug · For: Ulcerative Colitis; Crohn's Disease
- A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult ParticipantsPivotal-lookingNot yet recruiting
Gan & Lee Pharmaceuticals.Industry
NCT07920783 · 124 participants (planned) · Start Nov 5, 2026 · Primary completion Jul 30, 2027
Drug: GLR2053 Tablets; Placebo · For: Atopic Dermatitis
Sites: Beijing, China
Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
NCT07906145 · 76 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: QLS2416 Injection · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis (RA); Primary Sjögren's Syndrome (pSS) and 1 more
- A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic DermatitisNot yet recruiting
North Immunology Inc.Industry
NCT07904689 · 96 participants (planned) · Start Nov 2026 · Primary completion Jan 2030
Drug: NOR-101; Placebo · For: Atopic Dermatitis (AD)
Sites: Adelaide, Australia
Keymed Biosciences Co.LtdIndustry
NCT07900945 · 48 participants (planned) · Start Oct 2026 · Primary completion Sep 2027
Drug: CM551; Placebo and 2 more · For: Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Sites: Tianjin, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07873931 · 60 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 20, 2032
Drug: BMS-986553 · For: Systemic Lupus Erythematosus; Sjögren's Disease; Rheumatoid Arthritis and 3 more
Sites: Newport Beach, California; Worcester, Massachusetts; Ann Arbor, Michigan · 23 sites in all
- A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy AdultsNot yet recruiting
Shanghai Peptidstar Therapeutics LimitedIndustry
NCT07792928 · 40 participants (planned) · Start Oct 14, 2026 · Primary completion Nov 10, 2026
Drug: HCXT-2001 Tablets; Placebo and 4 more · For: Psoriasis
Sites: Takapuna, New Zealand; Christchurch, New Zealand; Grafton, New Zealand
- A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy VolunteersNot yet recruiting
EquilliumIndustry
NCT07869225 · 70 participants (planned) · Start Oct 2026 · Primary completion Apr 2027
Drug: EQ504; EQ504 Placebo · For: Ulcerative Colitis
Sites: Melbourne, Australia
- A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune DiseasesNot yet recruiting
PfizerPfizer (PFE)
NCT07782450 · 54 participants (planned) · Start Nov 19, 2026 · Primary completion Feb 22, 2031
Drug: PF-08154225 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis; Idiopathic Inflammatory Myositis and 1 more
- Phase 1b Clinical Study in Patients With Active Ulcerative ColitisNot yet recruiting
Thetis Pharmaceuticals LLCIndustry
NCT07834515 · 24 participants (planned) · Start Sep 16, 2026 · Primary completion Jul 29, 2027
Drug: TP317; Matching placebo · For: Ulcerative Colitis (UC)
- Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative ColitisNot yet recruiting
Attovia Therapeutics IncIndustry
NCT07819799 · 96 participants (planned) · Start Dec 14, 2026 · Primary completion Jul 15, 2028
Drug: ATTO-1091; Placebo · For: Ulcerative Colitis (UC)
- A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic DermatitisNot yet recruiting
Helixon Biotechnology (Suzhou) Co., LtdIndustry
NCT07801612 · 68 participants (planned) · Start Sep 2026 · Primary completion Oct 2027
Drug: HXN5003; Placebo and 2 more · For: Health Adult Subjects; Moderate-to-Severe Atopic Dermatitis
Sites: Hangzhou, China
- LMT503 First-in-human SAD, MAD, and FE StudyNot yet recruiting
Lmito Therapeutics Inc.Industry
NCT05659953 · 72 participants (planned) · Start Mar 1, 2027 · Primary completion Sep 1, 2027
Drug: LMT503; Placebo · For: Inflammatory Bowel Disease; Colitis, Ulcerative; Crohn Disease
Sites: Groningen, Netherlands
- R-3750 in Patients With Crohn's DiseaseNot yet recruiting
Rise Therapeutics LLCIndustry
NCT07791888 · 40 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 31, 2028
Drug: R-3750; Placebo · For: Crohn Disease (CD)
- A Basket Study of CTA313 in Participants With Active Autoimmune DiseasesNot yet recruiting
Imviva BioIndustry
NCT07783269 · 81 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: CTA313 UCAR T Cell Infusion · For: Systemic Lupus Erthematosus (SLE); Progressive Multiple Sclerosis (PMS); Autoimmune Encephalitis
- Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic DermatitisNot yet recruiting
Helixon Biotechnology (Suzhou) Co., LtdIndustry
NCT07782476 · 67 participants (planned) · Start Sep 2026 · Primary completion Oct 2027
Drug: HXN6005; Placebo and 4 more · For: Health Adult Subjects; Atopic Dermatitis (AD)
Sites: Hangzhou, China
- A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative ColitisNot yet recruiting
Helixon Biotechnology (Suzhou) Co., LtdIndustry
NCT07768254 · 32 participants (planned) · Start Sep 9, 2026 · Primary completion Apr 15, 2028
Drug: Biological: HX15001; Biological: HX15001 and 1 more · For: Colitis, Ulcerative
Sites: Hefei, China
Shenzhen MagicRNA Biotechnology Co., LtdIndustry
NCT07523282 · 12 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2027
Drug: HN2302 Injection · For: Autoimmune Disease; Systemic Lupus Erythematosus; Systemic Sclerosis (SSc)
Sites: Hefei, China
- A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative ColitisNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07760831 · 8 participants (planned) · Start Aug 2026 · Primary completion Apr 2027
Drug: HRS-7085 tablets; Placebo · For: Moderate to Severe Ulcerative Colitis
Sites: Chisinau, Moldova
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.